What is the appropriate dosing regimen of norethindrone to suppress menstruation?

Norethindrone Dosing for Menstrual Suppression

For menstrual suppression, norethindrone acetate 5 mg three times daily (15 mg/day total) is the most effective regimen, achieving bleeding cessation in 92% of patients within 3 days, compared to the standard contraceptive dose of 0.35 mg daily which is inadequate for suppression in most patients.

Standard Dosing Regimens

For Acute Menstrual Suppression (Short-Term)

• Start norethindrone acetate 5 mg three times daily (total 15 mg/day) when menstrual suppression is urgently needed 1
• Continue until 2 consecutive days without bleeding, then may taper or discontinue 2
• This regimen achieves bleeding cessation in 78.9% of patients within 7 days 2
• Superior to combined oral contraceptives for preventing breakthrough bleeding (8% vs 43% spotting rate, p<0.01) 1

For Chronic Menstrual Suppression

• Norethindrone acetate 10 mg daily is effective for ongoing suppression in patients with prolonged bleeding 3
• Achieves bleeding cessation in 86.7% of patients after 7 days of treatment 3
• Treatment can be repeated up to 3 times over 210 days as needed 3
• Results in significantly more bleeding-free days (21 vs 13 days in first 30 days, p=0.007) compared to placebo 3

Contraceptive Dose (Inadequate for Suppression)

• Norethindrone 0.35 mg daily continuously is FDA-approved for contraception only 4
• Must be taken at the same time every day without interruption 4
• This dose is insufficient for reliable menstrual suppression in most patients, particularly those with obesity, heavy menstrual bleeding, or younger age 5

Patient-Specific Dosing Considerations

Higher Doses Required For:

• Patients with obesity (BMI ≥25 kg/m²): Less likely to achieve suppression with 0.35 mg dose; consider norethindrone acetate 10-15 mg/day 5
• Heavy menstrual bleeding: Negatively associated with suppression at low doses; use norethindrone acetate 10-15 mg/day 5
• Younger patients: Less likely to achieve suppression despite more frequent prescribing of low-dose norethindrone 5
• Prolonged baseline bleeding: Associated with treatment failure at 0.35 mg dose 5

Patients Who May Use Lower Doses:

• Older adolescents with normal BMI and regular cycles may attempt 0.35 mg daily, but monitor closely for breakthrough bleeding 5
• Patients with disabilities report greater satisfaction with norethindrone for menstrual management 5

Critical Contraindications

Norethindrone acetate 10-20 mg daily converts to significant amounts of ethinyl estradiol (equivalent to 20-30 mcg), making it contraindicated in the same populations as combined hormonal contraceptives 6:

• Migraine with aura (absolute contraindication due to stroke risk) 7, 8
• History of venous thromboembolism (moderate dose-dependent risk increase) 6
• Active or history of arterial thromboembolic disease (stroke, myocardial infarction) 7
• Cyanotic heart disease, Fontan physiology, mechanical valves 8
• Breast cancer or estrogen-sensitive malignancies 7
• Active liver disease or hepatic tumors 7
• Pregnancy 7

Important Clinical Caveats

Estrogen Conversion Warning

• Therapeutic doses of norethindrone (10-20 mg/day) partially convert to ethinyl estradiol, unlike the 0.35 mg contraceptive dose 6
• This conversion creates similar thrombotic and stroke risks as combined oral contraceptives at therapeutic doses 6
• Contraceptive-dose norethindrone (0.35 mg) carries no increased VTE risk, but therapeutic doses may increase risk 6

Expected Side Effects

• Weight gain is common with norethindrone acetate 5 mg three times daily but resolves after cessation 1
• Heavier withdrawal bleeding occurs after stopping therapeutic doses compared to low-dose regimens (p<0.04) 1
• Shorter time to bleeding recurrence (5 vs 10.5 days) after stopping norethindrone acetate 10 mg compared to placebo 3
• Irregular bleeding is the most common reason for discontinuation (54.5% of discontinuations) 2

Timing Considerations

• Start by cycle day 12 for optimal suppression when delaying menses 1
• Patient satisfaction is significantly higher with norethindrone acetate (80% willing to repeat) compared to combined oral contraceptives 1
• Time to conception is shorter after norethindrone acetate compared to combined oral contraceptives (p<0.03) 1

Monitoring Requirements

• Baseline pregnancy test and blood pressure before initiating 7
• Screen for contraindications including cardiovascular disease, thrombophilia, and migraine with aura 7, 8
• Assess for breakthrough bleeding at 1,3, and 12 months 5
• No routine laboratory monitoring required for contraceptive doses 4

Common Prescribing Errors to Avoid

• Do not prescribe 0.35 mg daily for menstrual suppression in patients with obesity, heavy bleeding, or young age—use norethindrone acetate 10-15 mg/day instead 5
• Do not ignore estrogen-related contraindications when prescribing therapeutic doses (≥10 mg/day) of norethindrone acetate 6
• Do not use therapeutic-dose norethindrone acetate in patients with migraine with aura—the ethinyl estradiol conversion creates stroke risk 6
• Do not expect bleeding recurrence prevention—norethindrone acetate stops acute bleeding but does not prevent future episodes 3